Amgen to discuss application for new use of XGEVA® (denosumab) at FDA ODAC meeting
8 February 2012 | By Amgen
Amgen to discuss the data from the sBLA for XGEVA® (denosumab)...
List view / Grid view
News
Abbott creates new Similac SimplySmart™ baby bottle
8 February 2012 | By Abbott
Abbott introduces Similac SimplySmart, an innovative BPA-free baby bottle designed to improve the bottle feeding experience...
Merck announces top-line results of TRA-2P study of Vorapaxar
7 February 2012 | By Merck
Company will review data from TRA-2P and TRACER with external experts to inform next steps...
GSK injects $60 million and 58 jobs into Victoria
6 February 2012 | By F T I Consulting
GSK announced that it will invest $60 million to expand its manufacturing and new drug development activities in Victoria...
Merck provides update on development program for Suvorexant
6 February 2012 | By Merck
Company Confirms Plans to File NDA for Suvorexant in 2012...
Novartis drug Galvus® approved in EU for monotherapy use in patients with type 2 diabetes unable to take metformin
6 February 2012 | By Chamberlain Healthcare PR
The European Commission has approved the use of Galvus® (vildagliptin)...
Tecan and Artel partner to produce unique, fully integrated QC Kit for Freedom EVO® workstations
6 February 2012 | By kdm communications limited
Tecan has partnered with Artel...
Expiration of the Hart-Scott-Rodino waiting period for acquisition of Inhibitex, Inc.
3 February 2012 | By Bristol-Myers Squibb Company
Expiration of the HSR waiting period for acquisition of Inhibitex, Inc...
Boehringer Ingelheim, GWT and the TU Dresden sign diabetes research collaboration
3 February 2012 | By Boehringer Ingelheim
Research collaboration agreement to develop new insights into the causes of diabetes...
FDA approves JANUMET® XR (sitagliptin and metformin HCl extended-release) for type 2 diabetes
2 February 2012 | By Merck
JANUMET XR can help many patients reach blood sugar goals...
AstraZeneca to cut a further 7,300 jobs
2 February 2012 | By AstraZeneca
AstraZeneca has announced new restructuring initiatives designed to improve productivity and strengthen the company’s capabilities...
FDA approves Novartis drug Glivec® label
1 February 2012 | By Novartis
The US Food and Drug Administration has approved an update to the Glivec® (imatinib)* label...
Private and public partners unite to combat 10 neglected tropical diseases by 2020
30 January 2012 | By
Partners pledge innovative, coordinated action aimed at new WHO goals...
Novartis extends commitment to help achieve final elimination of leprosy
30 January 2012 | By Novartis
Novartis is a part of an international effort to eliminate or control 10 NTDs by the end of the decade...
FDA approves Jentadueto™ (linagliptin/metformin hydrochloride) tablets for the treatment of adult patients with type 2 diabetes
30 January 2012 | By Eli Lilly and Company
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto™ (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin. JENTADUETO provides a new, single-tablet treatment option, taken twice-daily, for patients who…
